A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

← catalyst calendar

NCT07728188 · readout ≤ 2,385 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 3

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

520estimated

Sites

Countries

Australia, Canada, France +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-11-30

estimated

When the study began enrolling

Primary completion

Feb 2033

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2033

estimated

The whole study's end, after follow-up

First posted

2026-07-27

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-27

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Relapsed or Refractory Multiple Myeloma

Interventions

Drug: Etentamig
Drug: Pomalidomide
Drug: Daratumumab
Drug: Dexamethasone
Drug: Carfilzomib
Drug: Teclistamab

Primary outcomes

what the primary-completion date above is the date OF

Safety Run-In: Number of Participants With Adverse Events (AE)s

measured Up to Approximately 75 Months

Randomized Portion: Complete Response (CR) or Better Rate Per Independent Review Committee (IRC) Assessment

measured Up to Approximately 75 Months

Randomized Portion: Progression-Free Survival (PFS) Per Independent Review Committee (IRC) Assessment

measured Up to Approximately 75 Months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed